You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
Benitec Biopharma Inc. reported positive interim Phase 1b/2a results for BB-301 in patients with OPMD: all treated patients were formal Responders, high dose showed greater 3-month swallowing improvements, and no Serious Adverse Events have occurred.
Benitec Biopharma Inc.’s annual stockholder meeting is scheduled for December 3, 2026 at 1:00 p.m. PT, with the Board recommending votes FOR director nominees, auditor ratification, and executive compensation.
Benitec Biopharma Inc. will hold its meeting virtually on December 3, 2026 at 1:00 p.m., Pacific Time to elect three Class I directors, ratify its independent registered public accounting firm and approve non-binding executive compensation.
Following FDA feedback, Benitec Biopharma Inc. said BB-301’s final pivotal study design is expected in 1Q 2027 and patient enrollment is planned for mid-2027; the FDA requested additional available data from the OPMD Natural History Study.
Benitec Biopharma Inc. engaged Ernst & Young LLP as its independent registered public accounting firm after EY completed client acceptance procedures, with the engagement letter executed on September 29, 2026 for the fiscal year ending June 30, 2027.
Benitec Biopharma Inc. dismissed Baker Tilly US, LLP and appointed Ernst & Young LLP for the fiscal year ending June 30, 2027, subject to client acceptance; Baker Tilly was notified of its dismissal on September 21, 2026.
